Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HMGCR | P04035 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16280043 | 0.88 | KDM4E (0.51) | KDM4EHTTCYP3A4TSHRGAA | |
| SCHEMBL14678626 | 0.88 | KDM4E (0.54) | KDM4EHTTTSHRGAAHMGCR | |
| SCHEMBL705665 | 0.87 | KDM4E (0.69) | KDM4EHTTCYP3A4TSHRGAA | |
| SCHEMBL30870738 | 0.87 | KDM4E (0.69) | KDM4EHTTCYP3A4TSHRGAA | |
| SCHEMBL7291805 | 0.86 | TSHR (0.62) | KDM4EHTTCYP3A4TSHRGAA | |
| SCHEMBL7300064 | 0.86 | TSHR (0.62) | KDM4EHTTCYP3A4TSHRGAA | |
| SCHEMBL21753969 | 0.84 | KDM4E (0.54) | KDM4EHTTCYP3A4TSHRGAA | |
| SCHEMBL6096678 | 0.83 | KDM4E (0.53) | KDM4EHTTCYP3A4TSHRGAA | |
| SCHEMBL4770365 | 0.83 | KDM4E (0.53) | KDM4EHTTCYP3A4TSHRGAA | |
| SCHEMBL7291265 | 0.82 | KDM4E (0.51) | KDM4EHTTCYP3A4TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382232-B2 | Quinoline and cinnoline derivatives and their applications | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2016-07-05 | — | — | US | disclosed |
| US-20140364431-A1 | Quinoline and cinnoline derivatives and their applications | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364431-A1 | Quinoline and cinnoline derivatives and their applications | MET, CHEK1, KIT | KDM4E 2948/4885HTT 3216/4885CYP3A4 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.